title: High-dose thiotepa, etoposide and carboplatin as conditioning regimen for autologous stem cell transplantation in patients with high-risk non-Hodgkin lymphoma.
abstract: High-dose chemotherapy conditioning regimens followed by autologous stem cell transplantation generally provide good results in non-Hodgkin lymphoma. We have evaluated the effects of a high-dose regimen comprising thiotepa, etoposide and carboplatin. After debulking and mobilization with high-dose cyclophosphamide or other schedules, forty-five patients at various disease stages were conditioned with thiotepa, etoposide and carboplatin prior to autologous stem cell transplantation. The overall response rate was 77.8% (30 CR, 66.7%; 5 PR, 11.1%). Ten patients (22.2%) did not respond. Two patients (4.4%) died from transplant-related complications. The mean 5-year overall survival was 71.1%: 12 patients relapsed within the first 5 years of follow-up. The overall response rate and 5-year overall survival were better for patients with an International Prognostic Index (IPI) 1 at diagnosis than for those with IPI 2 and IPI 3 (P<0.005 for all). The thiotepa, etoposide and carboplatin conditioning regimen for autologous stem cell transplantation in non-Hodgkin lymphoma has a good anti-lymphoma effect and provides encouraging results in terms of response to treatment and 5-year overall survival. Its good tolerance and acceptable toxicity suggest that it may a very useful in the management of non-Hodgkin lymphoma.
authors.affiliation: Department of Clinical and Experimental Medicine, Section of Hematology and Clinical Immunology, University of Perugia Medical School, Perugia, Italy.
authors.forename: Franca
authors.initials: F
authors.lastname: Falzetti
authors.forename: Mauro
authors.initials: M
authors.lastname: Di Ianni
authors.forename: Stelvio
authors.initials: S
authors.lastname: Ballanti
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Iodice
authors.forename: Antonia
authors.initials: A
authors.lastname: Reale
authors.forename: Olivia
authors.initials: O
authors.lastname: Minelli
authors.forename: Gabriella
authors.initials: G
authors.lastname: Serio
authors.forename: Massimo F
authors.initials: MF
authors.lastname: Martelli
authors.forename: Franco
authors.initials: F
authors.lastname: Dammacco
authors.forename: Angelo
authors.initials: A
authors.lastname: Vacca
authors.forename: Roberto
authors.initials: R
authors.lastname: Ria
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D016190:Carboplatin / Q000627:therapeutic use*; D018572:Disease-Free Survival; D005047:Etoposide / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D012307:Risk Factors; D016879:Salvage Therapy; D033581:Stem Cell Transplantation / Q000379:methods*; D013852:Thiotepa / Q000627:therapeutic use*; D019172:Transplantation Conditioning; D014182:Transplantation, Autologous; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D005047:Etoposide; D013852:Thiotepa; D016190:Carboplatin